NOV 17, 2021 6:00 AM PST

Aldosterone and Renin Measurements in the Management of Patients with Hypertension

Sponsored by: DiaSorin
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract
Date:  November 17, 2021
Time: 6:00am (PDT),  9:00am (EDT)
 
Primary Aldosteronism (PA) is a specifically treatable and potentially curable form of secondary hypertension. However, despite the recommendations of the Endocrine Society Guidelines and the European Society of Hypertension, Primary Aldosteronism is still largely underdiagnosed and undertreated. The Prevalence of PA among the general and resistant hypertensive population ranges from 5-20%.The Aldosterone to Renin Ratio (ARR) is routinely used as a screening test to diagnose Primary Aldosteronism in hypertensive individuals. The diagnostic algorithm also involves confirmation tests followed by lateralization studies to distinguish between unilateral and bilateral disease. PA requires a specific pharmacological treatment with mineralcorticoid receptors antagonist or with unilateral adrenalectomy. These treatments have shown to reduce the excess of cardiovascular risk characteristically associated with the disease. Reduced or absent compliance to anti-hypertensive treatments is a major obstacle to the achievement of blood pressure in patients with arterial hypertension. Current methods for therapeutic adherence assessment display low accuracy, limited applicability in clinical practice and/or high costs. Serial measurements of Aldosterone to Renin Ratio (ARR) were evaluated to assess the therapeutic compliance to RAAS inhibitors. A significant increase of renin levels and reduction of aldosterone levels after RAAS inhibitors initiation was observed with subsequent reduction of ARR. Delta ARR, defined as relative change before and after treatment initiation, provided high accuracy for determination of therapeutic compliance.
 
Learning Objectives
  • Improve awareness about Primary Aldosteronism true prevalence, as PA is currently underdiagnosed and under treated
  • Discuss the usefulness of Aldosterone to Renin Ratio as an aid for the clinical decision making. ARR to be recognized as the most sensitive screening test for differentiating primary from secondary causes of hypertension (Primary Aldosteronism).
  • Discuss the usefulness of Aldosterone and Renin measurements to address the therapy in Patients with Essential Hypertension
  • Discuss the effectiveness of Aldosterone and Renin measurements to assess drug adherence in patients with Hypertension
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
You May Also Like
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
NOV 09, 2022 8:00 AM PST
NOV 09, 2022 8:00 AM PST
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
OCT 12, 2022 8:00 AM PDT
OCT 12, 2022 8:00 AM PDT
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
Loading Comments...
Show Resources